Here’s your
Race Block Pack
Personalized by Ridli for Alex
- Electrolytes (sodium)500 mg
- Creatine Monohydrate5 g
- Magnesium Glycinate200 mg
- Omega-31 g
- Vitamin D32,000 IU
- Tart Cherry500 mg
Built on biotic science. Guided by Ridli. Delivered daily.
Confidential · November 2026
The problem
In our view, one-size-fits-all formulas are why most people never feel a difference, and why they stop.
Generic stacks ignore goals, sensitivities, and routines.
Nothing changes when life, training, or symptoms change.
Brands sell a bottle, then disappear until the next ad.
Most probiotics are made from dairy, soil, or animal strains. We start with Human Strain™: a clinically studied, human-origin Bifidobacterium adolescentis (B. adolescentis iVS-1®).
Investment case
R3VY is building a personalized nutrition platform that connects differentiated products, AI-guided relationships, and daily routines to create revenue for our brands and clients.
01 · Science
iVS-1® and KGA-10 create the starting point. Research informs the next candidates.
Shared foundation
Evidence + agents + human review. Execution across the full cycle.
02 · Commercial execution
Hero products lead to personalized routines, repeat purchases, and client services.
03 · Reusable learning
Evaluated workflows and permissioned records build reusable operating know-how.
Learning informs the next asset.
Every cycle strengthens execution.
New assets and services are a development thesis, not booked value. Prompt and trace value depends on rights, consent, evaluation, and reuse; no standalone valuation is assigned.
The wedge works
“A bowl of cereal doesn’t result in anywhere near the reaction it used to.”
“I’ve noticed higher tolerance for milk and dairy than before.”

Holy Cow!™ is a once-daily probiotic for lactose digestion support with occasional dairy; it is not a lactase enzyme. Quotes are from verified customers and reflect individual experience.
Future cast · Product development
R&DOnce-daily lactose digestion support is the commercial starting point.
Jr targets Q4 entry; a family bundle and optional enzyme gummies extend the routine.
Develop once-daily sleep and stress support capsules alongside the planned 2027 gummy formats.
Illustrative packaging. LIVE 2026 / LIVE Q4 / 2027 reflect management timing; future formats remain subject to formulation, claims, and launch review. Pediatric suitability requires review. The current Holy Cow!™ capsule is a probiotic; Lactase Enzyme Gummies are a separate planned product.
Commercial proof

Operating metrics are management reported. LTV is a company-reported estimate. Retention is a management estimate; cohort and period require reconciliation. Athlete experience is not proof of product efficacy or a guarantee of performance. Race result: 9&10 News, Nov. 9, 2026. Photo: Element Longevity.
The science moat · Biotic-to-venture platform
Once-daily lactose digestion support. The focused hero product behind Holy Cow!™ that opens the customer relationship.
A postbiotic candidate for sleep, mood, and stress propositions, and the basis of our next-brand concept.


Foundations describe the product strategy, not complete nutrition or treatment. KGA-10 remains subject to clinical, regulatory, IP, supply, and commercial diligence. Personalization and delivery extensions are proposed.
The platform
An AI nutrition companion that turns a single product into a personal routine. Text-first, with human guidance when needed.

Here’s your
Personalized by Ridli for Alex
Base 30-count probiotic + a monthly personalized sachet

I started with Holy Cow!™. What else can I build on?
Let’s look at your goals and current routine, then explore what may fit alongside your foundational product.
Next month’s pack
Reviewed with human guidance when needed.
Sleep’s been rough this week.
Noted. I’ll factor that into next month’s sachet and check in Friday.
Illustrative conversation. Ridli is not a diagnostic service. Consumer concept available; management reports an existing code foundation, and production readiness requires validation.
The Ridli hub
Ridli pulls supplements, labs, wearable data, and daily check-ins into one ongoing relationship. It learns what works for each person and updates their sachet every month, so every new data source makes the pack more specific and the customer stickier.
30-count bottle + monthly personalized sachet.
Blood work + microbiome testing.
Recovery, strain, and readiness.

100-mile race in 8 weeks. Sleep’s been rough. My gut tightens after hour four.
I’m on it. Here’s a stack built for this block — only what you need.
This month’s sachet
30-count bottle + monthly sachet. Ships to you.
Tonight: wind down earlier and cut caffeine after 2. I’ll check in tomorrow morning.
Fueling for your training block.
Wind-down and recovery habits.
Base, a clinically studied probiotic, plus gut check-ins.
Lab, wearable, and coaching integrations are in development. Illustrative conversation. Ridli is not a diagnostic service.
How it compounds
A focused gut or mind foundation customers can feel.
New goals and questions bring Ridli in.
Eligible additions, chosen with guidance, in the monthly pack.
Feedback informs the next routine, and the next order.
Every check-in feeds the next month
For consumers
Customers start with a focused product, then ask for more. Ridli connects education, preferences, and check-ins to appropriate additions over time.
For practitioners
The proposed extension connects approved practice knowledge and permissioned client context, with practitioners reviewing recommendations.
Consumer concept available. Management reports an existing code foundation; production readiness and practitioner data isolation require validation. Ridli is not a diagnostic service.
Shared engine
AI agent workflows describe the operating model and development thesis; outcomes are not booked value.
Personalization + fulfillment
Invest in differentiated hero products. Use qualified dropship partners for traditional ingredients that complement the routine.
Foundation


iVS-1® leads today. KGA-10 is a candidate for the next evidence-led proposition, subject to diligence.
Orchestration
Permissioned context, approved evidence, and human review inform eligible selections. MCP is the proposed tool-connection layer.
Asset-light expansion
Qualified partners fulfill eligible complementary products. R3VY directs development capital toward more differentiated heroes, rather than owning every SKU.
Own the heroes. Expand the routine through partners.
Proposed architecture, not a verified live integration or a commitment to supply any ingredient. Safety, claims, data consent, catalog availability, and unit economics are launch gates.
Portfolio

Daily lactose digestion support, growing into a carefully tested family of formats.

Here’s your
Personalized by Ridli for Alex
Biotic routines for training and everyday movement.
Ridli Coach “What are you training for? Let’s build your routine.”



Strain-specific nutrition for practices and clients.
Ridli Guide “Share your goals. Let’s prepare a plan with your practitioner.”

A NeuroAlly™ KGA-10 opportunity for sleep, mood, and stress.
Great Brain Day is a concept subject to evidence, formulation, and launch review. Product images are illustrative packaging.
Go-to-market
A familiar expression and a ready-made creative hook. Creator clips drive discovery; DTC and Amazon handle purchase and replenishment.

Specialty-store pilots pair staff education, clubs, and coaches with QR-led AI onboarding.

SMS-first intake, strain education, practitioner review, and private product ordering.
Store pilots and practitioner access are proposed; AI and partner workflows are in development; placements and outcomes are not assumed.
Four-year financial path
Financial outlook figures are management projections and forward-looking statements, not guarantees. 2026 reflects 10 months of actuals plus 2 months forecast; 2027–2029 are forecasts.
Four-year outcome
A strategic acquirer buys the portfolio, differentiated strain access, clinical evidence, customer data, and AI operating system together.
A category winner such as Holy Cow!™ exits independently while R3VY keeps the engine, science base, and remaining portfolio upside.
Strategic buyers are paying for science, trust, and channel reach
The case is not size parity. It is buyer appetite for differentiated, science-led wellness brands with trusted channels.
2029 value and value-to-cap ratio are illustrative and forward-looking. GRÜNS and Thorne values were publicly reported; Unilever did not disclose the GRÜNS purchase price. Nutrafol reflects €811M converted at the ECB reference rate on July 7, 2022, for a further 67% (total ownership 80%). Bountiful from buyer disclosure.
Team

Co-founder & CEO
Scaled a health-and-wellness startup to $30M in annual revenue. Leads architecture, capital strategy, and AI-native systems.

Co-founder & CMO
Growth marketer who has scaled consumer brands to tens of millions in revenue. Leads positioning, acquisition, and growth.

CXO
Leads product strategy, scientific translation, supplier relationships, customer experience, and brand development.

Lead investor · Board-certified gastroenterologist
“Connecting the right science, ingredients, and products to specific human needs.”
The ask
Retain the team. Protect inventory. Scale measured acquisition and develop the next heroes.
Closed: $200K direct equity + two $50K SAFEs. Separately, $116,167.96 in founder/partner capital brings total funding to $416,167.96.
Use of funds · Prior six-month spending mix
Use-of-funds percentages reflect the prior six-month spending mix, shown as a guide to how capital is deployed; they are not a commitment for future allocation.
Let’s build the future of personal nutrition.
Built on biotic science. Guided by Ridli. Delivered daily.
Co-founder & CEO · R3VY
Hero products.
Personal relationships.
One shared platform.
Confidential · Investor discussion · November 2026
Appendix
Confidential. This presentation is for discussion with prospective investors only and is not an offer to sell or a solicitation of an offer to buy securities.
Operating metrics. Direct orders, LTV, CAC, LTV/CAC, peak MoM growth, finished-unit cost, retail product margin, rating, and retention are management reported. LTV is a company-reported estimate. Retention is a management estimate; cohort and period require reconciliation. Margin is at $45 retail before channel costs.
Forward-looking statements. The financial outlook (2026–2029), first profitable month and year, illustrative 2029 value, and value-to-cap ratio are projections and illustrations, not guarantees. 2026 reflects 10 months actual plus 2 months forecast.
Development thesis. New assets, brands, and services are a development thesis, not booked value. NeuroAlly™ KGA-10 remains subject to clinical, regulatory, IP, supply, and commercial diligence. Future formats and timing remain subject to formulation, claims, and launch review; pediatric suitability requires review.
Ridli. Ridli is not a diagnostic service. The consumer concept is available; management reports an existing code foundation, and production readiness and practitioner data isolation require validation. Conversations shown are illustrative.
Personalization and fulfillment. Partner fulfillment and tool-connection layers are proposed architecture, not a verified live integration or a commitment to supply any ingredient. Safety, claims, data consent, catalog availability, and unit economics are launch gates. Prompt and trace value depends on rights, consent, evaluation, and reuse; no standalone valuation is assigned.
Products. Holy Cow!™ is a probiotic, not a lactase enzyme. Customer quotes reflect individual experience. Packaging shown may be illustrative.
Athlete. Athlete experience is not proof of product efficacy or a guarantee of performance. Race result: 9&10 News, Nov. 9, 2026. Photo: Element Longevity.
Comparable transactions. GRÜNS and Thorne values were publicly reported; Unilever did not disclose the GRÜNS purchase price. Nutrafol reflects €811M converted at the ECB reference rate on July 7, 2022; Unilever bought a further 67%, bringing total ownership to 80%. Bountiful comes from buyer disclosure. The valuation case is not size parity.
Use of funds. Percentages reflect the prior six-month spending mix.
© 2026 R3VY. All rights reserved.